Dr. Andrew Adams, PhD - Lilly Institute for Genetic Medicine - Targeting Root Causes Of Diseases

Dr. Andrew Adams, Ph.D. is Vice President of Neurodegeneration Research at Eli Lilly (https://www.lilly.com/) and Co-Director of their new Lilly Institute for Genetic Medicine (https://lilly.mediaroom.com/2022-02-22-Lilly-Announces-the-Institute-for-Genetic-Medicine-and-700-Million-investment-in-Boston-Seaport-Site), a $700 million initiative to establish an institute for researching and developing genetic medicines, specifically acting at the nucleic acid level, to advance an entirely new drug class that target the root cause of diseases, an approach that is fundamentally different than medicines available today.

In this role, Dr. Adams will be responsible for leading the discovery of various new types of therapies, via both internal research, and robust collaborations with external partners.

These novel approaches will also allow Lilly access to previously "undruggable" targets across the breath of therapeutic areas at Lilly, as well as potentially opening up novel avenues of clinical investigation.

In addition to these major roles, Dr. Adams over the recent years also took on scientific leadership of Lilly’s COVID-19 neutralizing antibody projects, as well as serving as Vice President for Lilly Genetic Medicine, and during his time at Lilly has served in roles across early discovery, external innovation, and as a leader of Lilly’s early trailblazer teams, championing new ways to bring Lilly science to patients with speed.

Dr Adams holds a degree in biology and a doctorate in zoology from the University of Aberdeen, Scotland. Prior to joining Lilly in 2011, he was a postdoctoral fellow at Harvard Medical School studying the neurobiology of anorexia nervosa.